Stephen Shumack

Stephen Shumack

Auto-generated profile, based on publicly available information

Stephen Shumack

Department of Dermatology Royal North Shore Hospital St Leonard's New South Wales Australia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
MLMark Lebwohl
Mark Lebwohl
SSStephen Shumack
Stephen Shumack
LGLinda Stein Gold
Linda Stein Gold
AMAnita Melgaard
Anita Melgaard
TLThomas Larsson
Thomas Larsson
STStephen K. Tyring
Stephen K. Tyring
Actinic keratoses are common in light-skinned individuals who spend a significant amount of time in geographic areas with moderate to high levels of solar radiation. They are considered premalignant lesions, with a small but definite risk of transformation into squamous cell carcinoma.1 Cryotherapy with liquid nitrogen is the most widely used therapy for actinic keratoses.2 This treatment may be associated with significant recurrence rates in the area treated because therapy is aimed only at the individual actinic keratoses, so-called spot therapy. Several other therapies are applied to an entire field of sun-damaged skin, so-called field therapy. These field therapies include fluorouracil cream,3 imiquimod cream,4 diclofenac sodium gel,5 and photodynamic therapy.6 The advantages of field therapy include the fact that subclinical and clinically evident actinic keratoses are treated, and the recurrence rates over the treated areas are significantly lower compared with those seen following spot therapy.3-6

12 February 2024 in Australian and New Zealand Journal of Public Health
Verified
Journal Article
Open access
RNRachel Neale
Rachel Neale
VBVictoria Beedle
Victoria Beedle
PEPeter R. Ebeling
Peter R. Ebeling
TEThomas Elliott
Thomas Elliott
DFDavid Francis
David Francis
DWDavid C. Whiteman
David C. Whiteman
To describe the development of a new position statement regarding balancing the risks and benefits of sun exposure for Australian adults. We conducted a Sun Exposure Summit in March 2021, with presentations from invited experts and a workshop including representation from academic, clinical, policy, and patient stakeholder organisations. The group considered advice about balancing the risks and benefits of sun exposure for Australian adults and developed a revised consensus position statement. The balance of risks and benefits of sun exposure is not the same for everybody. For people at very high risk of skin cancer, the risks of exposure likely outweigh the benefits; sun protection is essential. Conversely, people with deeply pigmented skin are at low risk of skin cancer but at high risk of vitamin D deficiency; routine sun protection is not recommended. For those at intermediate risk of skin cancer, sun protection remains a priority, but individuals may obtain sufficient sun exposure to maintain adequate vitamin D status. The new position statement provides sun exposure advice that explicitly recognises the differing needs of Australia's diverse population. Mass communication campaigns should retain the focus on skin cancer prevention. The new position statement will support the delivery of personalised advice.

20 September 2022 in Australasian Journal of Dermatology
Verified
Journal Article
Open access
PFPeter Foley
Peter Foley
YKYves A. Kerdraon
Yves A. Kerdraon
JHJohn P. Hogden
John P. Hogden
SSStephen Shumack
Stephen Shumack
LSLynda Spelman
Lynda Spelman
CKConstance H. Katelaris
Constance H. Katelaris
Background/Objectives: Dupilumab‐associated ocular surface disease (DAOSD) is of particular relevance in patients with atopic dermatitis (AD). Guidance on DAOSD assessment and management in the Australian setting is needed to reduce its impact and minimise disruption to treatment.Methods: A systematic review of the literature was undertaken to identify data pertaining to the incidence, pathophysiology, risk factors and management of DAOSD. A critical review of this literature was used to inform a decision framework for dupilumab‐prescribers and develop a graded severity scoring tool to guide appropriate management options.Results: DAOSD typically emerges within 4 months of commencing dupilumab and the occurrence of new events diminishes over time. The reported incidence varies widely depending on the nature and source of the data: 8.6–22.1% (clinical trials programme), 0.5–70% (real‐world data; differences in study size, duration of follow‐up, ophthalmologist intervention, use of prophylaxis). Occurrence increases with AD severity and in patients with prior history of ocular disease; pathophysiology is still to be fully characterised. Management options have evolved over time and include lubricants/artificial tears, corticosteroids, calcineurin inhibitors, antihistamines, anti‐inflammatory agents and antimicrobial agents. Current therapies aim to resolve symptoms or reduce severity to levels sufficiently tolerable to enable continuation of dupilumab therapy.Conclusions: Recommendations for DAOSD assessment and management include identification of high‐risk patients, vigilance for red flags (keratoconus, herpetic and bacterial keratitis), regular assessment of symptom severity (before and during dupilumab therapy), conservative management of mild DAOSD by the prescribing physician and ophthalmologist referral for collaborative care of moderate–severe DAOSD and high‐risk patients.

2 January 2023 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
STStephen Tyring
Stephen Tyring
PRPhoebe Rich
Phoebe Rich
YTYayoi Tada
Yayoi Tada
SBStefan Beeck
Stefan Beeck
IMIzabella Messina
Izabella Messina
SSStephen Shumack
Stephen Shumack
Introduction Atopic dermatitis (AD) is a heterogeneous disease, with involvement of the T-helper cell (Th) 2, Th22, and potentially Th17 pathways, supporting the use of interleukin (IL)-23 and IL-22 blockade in AD. Methods This phase 2, multicenter, randomized, double-blind, placebo-controlled trial (NCT03706040) evaluated the efficacy and safety of risankizumab, an IL-23 inhibitor, in patients (≥ 12 years old) with moderate-to-severe AD, defined by an Eczema Area and Severity Index (EASI) ≥ 16, affected body surface area ≥ 10%, and a Validated Investigator Global Assessment for AD (vIGA-AD) score ≥ 3. Patients were randomized 2:2:1 to 16-week treatment with risankizumab 150 mg, risankizumab 300 mg, or placebo in period A; patients receiving placebo were re-randomized 1:1 to risankizumab 150 mg or 300 mg and patients receiving risankizumab continued on their randomized dose in 36-week period B. Study drug was administered at baseline and weeks 4, 16, 28, and 40. The primary endpoint was the proportion of patients achieving a ≥ 75% reduction from baseline in EASI (EASI 75) at week 16. Safety was analyzed in all randomized patients who received study medication. Results Neither the risankizumab 150 mg (n = 69) nor the 300 mg dose group (n = 69) demonstrated a significantly higher proportion of patients achieving EASI 75 at week 16 compared with the placebo group (n = 34; treatment difference [95% CI] 13.0% [–1.7 to 27.7%; P = 0.084] and 10.0% [–4.6 to 24.6%; P = 0.179], respectively). Most adverse events were mild to moderate in severity; five patients receiving risankizumab reported serious adverse events, including two patients who reported cellulitis. Conclusions Risankizumab was generally well tolerated, with no new safety concerns identified. The study’s primary endpoint was not met, with no significant difference in the proportion of patients achieving an EASI 75 response at week 16 with risankizumab 150 mg or 300 mg versus placebo. Trial Registration ClinicalTrials.gov NCT03706040.

12 November 2003 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
DTDiana Tran
Diana Tran
Steven KossardSteven Kossard
Steven Kossard
SSStephen Shumack
Stephen Shumack

28 July 2023 in Australasian Journal of Dermatology
Verified
Journal Article
Open access
PFPeter Foley
Peter Foley
KGKurt Gebauer
Kurt Gebauer
JSJohn Sullivan
John Sullivan
EMErin McMeniman
Erin McMeniman
SSStephen Shumack
Stephen Shumack
CBChristopher Baker
Christopher Baker
Background: Over the last decade, the treatment landscape for moderate–severe psoriasis has rapidly evolved. The Australasian College of Dermatologists sought to review and update previously published treatment goals for moderate–severe psoriasis.Methods: A modified Delphi approach was used. Comprehensive literature review and guideline evaluation resulted in the development of statements and other questions to establish current clinical practices. Two rounds of anonymous voting were undertaken, with a collaborative meeting held in between to discuss areas of discordance. Overall, consensus was defined as achievement of ≥75% agreement in the range 7–9 on a 9‐point scale (1 strongly disagree; 9 strongly agree).Results: Consensus was achieved on 26/29 statements in round 1 and a further 20 statements in round 2. There was strong agreement to expanding the classification/definition of psoriasis severity by including a choice of metrics, incorporating quality of life measures, and widening the scope of high‐impact sites. Consensus was also reached on revised treatment response criteria, which were then incorporated into a new treatment algorithm. There was discordance with the current requirement to undertake a trial with established systemic agents before accessing targeted therapy.Conclusion: The ability of new targeted treatment options to change the narrative in psoriasis patient care can only be properly realised if challenges to timely and equitable access are addressed. The proposed framework for the assessment, classification and management of moderate–severe psoriasis aligns with international recommendations. Its adoption into Australian clinical practice is hoped to improve treatment outcomes and patients' satisfaction with their care.